MedTrace Logo

Novel Peptide Vaccination for Patients With Advanced Renal Cell Carcinoma

NCT01254838 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2010-12-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and CTL reaction of novel peptide vaccination for advanced renal cell carcinoma

Conditions

Interventions

BIOLOGICAL

HLA-A02 restricted HIG2

Sponsors & Collaborators

  • Human Genome Center, Institute of Medical Science, University of Tokyo

    collaborator OTHER

  • Iwate Medical University

    lead OTHER

Principal Investigators

  • Tomoaki Fujioka · Department of Urology, Iwate Medical University

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2010-12-31
Completion
2010-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01254838 on ClinicalTrials.gov